Paper Details

  1. Home
  2. Paper Details

Survivin-targeted nanomedicine for increased potency of abiraterone and enzalutamide against prostate cancer.

Author: Al-RejaieSalim S, BakerAbu, ElgorbanAbdallah M, MohanyMohamed, Sajid KhanMohd, SyedAsad

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A new nanomedicine called AbEzSvGNPs was developed to treat prostate cancer. AbEzSvGNPs contain abiraterone and enzalutamide, two drugs used to treat prostate cancer, and they are delivered to cancer cells using gold nanoparticles. AbEzSvGNPs were found to be effective in killing prostate cancer cells and were safe for healthy cells.
Paper Details　
Original Abstract of the Article :
Prostate cancer is the leading and most aggressive cancer around the world, several therapeutic approaches have emerged but none have achieved the satisfactory result. However, these therapeutic approaches face many challenges related to their delivery to target cells, including their in vivo decay,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejpb.2023.10.005

データ提供：米国国立医学図書館（NLM）

Nanomedicine Targets Survivin to Enhance Prostate Cancer Therapy

Prostate cancer is a major health concern worldwide, with limited treatment options. This study explores a novel approach using nanomedicine to deliver a combination of existing drugs, abiraterone and enzalutamide, directly to prostate cancer cells, targeting the survivin protein, a key player in cancer cell survival.

A Targeted Approach to Combatting Prostate Cancer

Researchers developed a nanomedicine system comprising abiraterone and enzalutamide encapsulated in survivin-targeted gold nanoparticles. This targeted delivery system demonstrated synergistic effects against prostate cancer cells, enhancing the potency of the drugs while minimizing side effects on healthy cells. The study also revealed the mechanism of action involving multiple signaling pathways in prostate cancer cells.

Hope on the Horizon for Prostate Cancer

This study offers a promising avenue for developing more effective and safer treatments for prostate cancer. The potential of nanomedicine to deliver drugs specifically to cancer cells while minimizing damage to healthy cells represents a significant advancement in cancer therapy.

Dr. Camel's Conclusion

This study is like a camel caravan equipped with advanced navigation technology, delivering a targeted and potent payload of abiraterone and enzalutamide directly to the heart of prostate cancer cells. The potential of this nanomedicine system is exciting, offering a glimmer of hope for a more effective and personalized approach to combating this challenging disease.

Date :
  1. Date Completed 2023-11-06
  2. Date Revised 2023-11-06
Further Info :

Pubmed ID

37797680

DOI: Digital Object Identifier

10.1016/j.ejpb.2023.10.005

Related Literature

Article Analysis
・Side Effects of abiraterone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.